Suboxone (buprenorphine/naloxone) and methadone are the two primary medications for opioid use disorder (OUD), and both reduce illicit opioid use by 60 to 80 percent and cut overdose death rates by more than 50 percent. They work through different pharmacological mechanisms: methadone is a full mu-opioid agonist dispensed daily at specialised clinics, while Suboxone is a partial agonist that can be prescribed by office-based physicians and taken at home. Neither is superior in all cases; the best choice depends on the severity of the addiction, the person’s life circumstances, access to clinics, and individual response.
Why Medication-Assisted Treatment Works
“The question should not be ‘Suboxone or methadone,’ but rather ‘which medication best fits this person’s clinical situation and life,'” says Dr. Ponlawat Pitsuwan, Physician at Phuket Island Rehab. “Both medications have decades of evidence behind them. Both save lives. The choice between them depends on factors that are specific to the individual, and changing from one to the other during treatment is entirely appropriate if the first choice is not working.”
Both medications work by occupying the same mu-opioid receptors that heroin, fentanyl, and prescription opioids target. By keeping these receptors occupied with a controlled, stable medication, MAT prevents withdrawal symptoms, reduces cravings, and blocks or diminishes the euphoric effects of illicit opioids. This allows the brain’s reward system to begin normalising without the repeated cycles of intoxication and withdrawal that drive compulsive use.
How Methadone Works
Methadone is a synthetic, full mu-opioid agonist with a long half-life of 24 to 36 hours. It activates opioid receptors fully but at a slow, sustained rate that produces stability rather than euphoria when dosed correctly. This full agonist action means methadone can adequately relieve withdrawal and cravings even in people with very high opioid tolerance, making it particularly effective for severe opioid addiction.
Methadone is dispensed as a liquid at specialised opioid treatment programmes (OTPs) and is typically administered under direct observation, at least initially. Patients who demonstrate stability over time may earn “take-home” doses, reducing the frequency of clinic visits. Doses typically range from 60 to 120 mg per day, individually titrated based on clinical response.
The primary advantages of methadone are its effectiveness in severe addiction, its long track record (used since the 1960s), and its ability to hold patients with very high opioid tolerance. The primary disadvantages are the requirement for daily clinic visits (which can conflict with employment and travel), the risk of respiratory depression if doses are too high or if combined with benzodiazepines or alcohol, and the prolonged withdrawal if methadone itself is discontinued (up to 14 to 21 days).
How Suboxone Works
Suboxone combines two medications: buprenorphine (a partial mu-opioid agonist) and naloxone (an opioid antagonist). Buprenorphine activates opioid receptors but only partially, producing a “ceiling effect” where increasing the dose beyond a certain point does not produce additional opioid effects. This ceiling makes buprenorphine significantly safer than methadone in terms of respiratory depression risk. The naloxone component is included to discourage injection: when taken sublingually as intended, naloxone is not absorbed; if injected, it precipitates withdrawal.
Suboxone can be prescribed by physicians, nurse practitioners, and physician assistants in office-based settings, eliminating the need for daily clinic visits. Patients typically receive prescriptions for weekly or monthly supplies. Doses range from 8 to 24 mg of buprenorphine per day.
The primary advantages of Suboxone are its safety profile (ceiling effect makes overdose very difficult), office-based prescribing (greater convenience and reduced stigma), and shorter withdrawal duration if discontinued (7 to 14 days). The primary disadvantages are that it may not adequately suppress cravings in people with very high opioid tolerance, the induction process requires the patient to be in mild withdrawal before the first dose (to avoid precipitated withdrawal), and the induction from fentanyl specifically requires careful micro-dosing protocols.
| Feature | Methadone | Suboxone (Buprenorphine/Naloxone) |
|---|---|---|
| Receptor action | Full mu-opioid agonist | Partial mu-opioid agonist |
| Dispensing | Daily at OTP clinic (initially) | Office-based prescription, take-home supply |
| Ceiling effect | No (dose-dependent respiratory depression) | Yes (safer in overdose) |
| Efficacy for severe addiction | Excellent (can match any tolerance level) | Good to excellent (may be insufficient at very high tolerance) |
| Induction | Can start immediately; no withdrawal required | Must be in mild withdrawal first (or use micro-dosing protocol) |
| Withdrawal duration if discontinued | 14 to 21 days | 7 to 14 days |
| Overdose risk | Higher (especially with sedatives) | Lower (ceiling effect) |
| Evidence for mortality reduction | Over 50% reduction | Over 50% reduction |
The Third Option: Naltrexone
A third MAT option, naltrexone (Vivitrol), works differently from both methadone and Suboxone. Naltrexone is a full opioid antagonist that blocks all opioid effects, producing no opioid activation whatsoever. It is available as a daily oral tablet or a monthly extended-release injection. Naltrexone is most appropriate for highly motivated patients who have completed detoxification and want a medication that makes opioid use physiologically unrewarding.
Naltrexone’s primary limitation is that it requires complete opioid abstinence before initiation (7 to 10 days opioid-free), making it impractical for many patients in the acute phase of addiction. Retention rates are lower than for methadone or Suboxone because the medication does not relieve cravings and does not prevent withdrawal. However, for patients who can initiate and maintain it, the monthly injection format eliminates daily adherence challenges.
Choosing Between Methadone and Suboxone
Clinical guidelines do not declare one medication superior to the other. The choice is individualised based on several factors. Methadone may be preferred when the person has very high opioid tolerance and needs full agonist coverage, when previous attempts with buprenorphine did not adequately control cravings, when the person benefits from the daily structure and accountability of clinic attendance, or when the person is using fentanyl and induction onto buprenorphine carries high precipitated withdrawal risk.
Suboxone may be preferred when the person’s employment, childcare, or geographic location makes daily clinic attendance impractical, when a safer medication profile is important (history of co-occurring benzodiazepine or alcohol use), when the person values privacy and wants to avoid the stigma associated with methadone clinics, or when the addiction severity is moderate rather than severe.
Both medications can and should be combined with psychotherapy, group support, and lifestyle changes. Medication alone stabilises brain chemistry; therapy addresses the behavioural, emotional, and social dimensions of addiction. At Phuket Island Rehab, MAT is integrated with comprehensive rehabilitation programming, ensuring that medication is one component of a holistic treatment plan rather than a standalone intervention.
Addressing the “Substitution” Myth
The most persistent barrier to MAT acceptance is the belief that it “substitutes one addiction for another.” This framing misunderstands both the pharmacology and the clinical reality. Addiction is characterised by compulsive use despite harm, loss of control, and escalation. MAT produces none of these: methadone and Suboxone at therapeutic doses do not produce euphoria, impairment, or escalation. They stabilise receptor activity at a level that prevents both withdrawal and the reward-driven use cycle.
The analogy most clinicians use is insulin for diabetes: insulin does not “substitute one disease for another.” It manages a chronic condition by providing what the body cannot produce on its own. Similarly, MAT manages a chronic brain condition by providing stable opioid receptor activity that the brain’s damaged endorphin system cannot maintain independently. The person on MAT can work, maintain relationships, care for children, and engage in therapy. The person in active addiction cannot.
When Opioid Use Has Become More Than Occasional
If you are using opioids daily, if you have developed tolerance, if you experience withdrawal symptoms when you miss a dose, and if your use has escalated beyond your original intention, you have opioid use disorder. MAT is the evidence-based first-line treatment, and choosing between methadone and Suboxone is a medical decision best made with a clinician who understands your specific situation.
Summary
Methadone and Suboxone are both highly effective medications for opioid use disorder, each reducing illicit use by 60 to 80 percent and cutting overdose mortality by more than 50 percent. Methadone offers full agonist coverage suited to severe addiction but requires daily clinic visits. Suboxone offers a safer ceiling effect and office-based prescribing convenience but may not hold patients with the highest tolerance levels. Neither is inherently better; the right choice depends on the individual’s clinical needs, life circumstances, and treatment response.
“The best medication is the one the patient will take consistently,” says Dr. Ponlawat Pitsuwan. “If methadone keeps someone alive and stable, that is the right medication for them. If Suboxone allows someone to maintain their job and their family while recovering, that is the right medication for them. The wrong choice is no medication at all, and the evidence on that point is unambiguous.”
Frequently Asked Questions
How long should someone stay on MAT?
Current evidence supports long-term and potentially indefinite MAT for many patients. Discontinuation, even after years of stability, carries a significant relapse risk: studies show relapse rates of 50 to 80 percent within six months of MAT discontinuation. The decision to taper should be made collaboratively between patient and clinician, with a slow taper over months and close monitoring. There is no medical requirement to stop MAT, and many patients benefit from indefinite maintenance.
Can I switch from methadone to Suboxone or vice versa?
Yes. Switching from Suboxone to methadone is straightforward and can be done without a gap. Switching from methadone to Suboxone is more complex because buprenorphine (the active component of Suboxone) can precipitate withdrawal if introduced while methadone is still active. The standard approach is to taper methadone to 30 mg per day or less, wait 24 to 72 hours, and then begin Suboxone when withdrawal symptoms appear. Micro-dosing protocols are increasingly used to make this transition smoother.
Will MAT show up on a drug test?
Standard workplace drug panels do not test for buprenorphine or methadone. However, extended panels used in some clinical and legal settings can detect both. Patients on prescribed MAT should inform the testing entity that they are taking prescribed medication, which is a legitimate medical treatment. In most jurisdictions, a positive result for a prescribed medication cannot be used as a basis for employment discrimination.
Can I drink alcohol while on MAT?
Alcohol combined with any opioid, including MAT medications, increases the risk of respiratory depression and overdose. This risk is higher with methadone (a full agonist) than with Suboxone (which has a ceiling effect), but both carry risk. Alcohol use disorder is common among people with OUD, and co-occurring alcohol use should be addressed as part of the treatment plan. Drinking while on MAT is medically inadvisable and clinically concerning.
Is MAT available in Thailand?
Thailand has methadone maintenance programmes primarily through government hospitals and specialised addiction clinics. Buprenorphine availability is more limited but expanding. At Phuket Island Rehab, opioid use disorder treatment includes medically supervised withdrawal, MAT initiation where appropriate, and comprehensive rehabilitation. Patients who will continue MAT after treatment can be stabilised and connected with ongoing prescribing services in their home country.
What happens if I use heroin or fentanyl while on Suboxone?
Because buprenorphine has high receptor affinity, it partially blocks the effects of other opioids. Using heroin or fentanyl on top of Suboxone will produce a diminished effect compared to using without Suboxone. However, this is not complete blockade, particularly with high-potency fentanyl, and overdose is still possible, especially if the person uses large amounts to overcome the partial blockade. Using illicit opioids while on MAT indicates that the treatment plan needs adjustment, not that MAT has failed.
Sources:
Mattick, R. P. et al. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, (2), CD002207.
Substance Abuse and Mental Health Services Administration (2020). TIP 63: Medications for Opioid Use Disorder. SAMHSA.
Sordo, L. et al. (2017). Mortality risk during and after opioid substitution treatment. BMJ, 357, j1550.
National Academies of Sciences, Engineering, and Medicine (2019). Medications for Opioid Use Disorder Save Lives. The National Academies Press.
Medication-assisted treatment, MAT, Suboxone, buprenorphine, naloxone, methadone, naltrexone, Vivitrol, mu-opioid receptor, full agonist, partial agonist, antagonist, ceiling effect, opioid treatment programme, OTP, precipitated withdrawal, micro-dosing induction, opioid use disorder, OUD, SAMHSA, TIP 63, Cochrane, Phuket Island Rehab